Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Characterization of the first symptoms of multiple sclerosis in a Brazilian center: cross-sectional study.

Cavenaghi VB, Dobrianskyj FM, Olival GSD, Carneiro RPCD, Tilbery CP.

Sao Paulo Med J. 2017 May-Jun;135(3):222-225. doi: 10.1590/1516-3180.2016.0200270117.

2.

The cerebrospinal fluid in multiple sclerosis: far beyond the bands.

Domingues RB, Fernandes GBP, Leite FBVM, Tilbery CP, Thomaz RB, Silva GS, Mangueira CLP, Soares CAS.

Einstein (Sao Paulo). 2017 Jan-Mar;15(1):100-104. doi: 10.1590/S1679-45082017RW3706. Review. English, Portuguese.

3.

MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.

Dias-Carneiro RP, von Glehn F, Moraes AS, Boldrini VO, Damasceno A, Andrade MD, Lima AC, Casanova CS, Tilbery CP, Damasceno BP, Santos LM, Brandão CO.

J Neuroimmunol. 2016 Nov 15;300:30-35. doi: 10.1016/j.jneuroim.2016.10.001. Epub 2016 Oct 5.

PMID:
27806873
4.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

5.

Olfactory alterations in patients with multiple sclerosis.

Jordy SS, Starzewski A Junior, Macedo FA, Manica GR, Tilbery CP, Carabetta EG.

Arq Neuropsiquiatr. 2016 Sep;74(9):697-700. doi: 10.1590/0004-282X20160128.

6.

Polyomavirus detection in multiple sclerosis patients under natalizumab therapy: Profile and frequency of urinary shedding.

Nali LH, Fink MC, do Olival GS, Moraes L, Callegaro D, Tilbery CP, Vidal JE, Sumita LM, de Oliveira AC, Romano CM.

J Med Virol. 2017 Mar;89(3):528-534. doi: 10.1002/jmv.24646. Epub 2016 Aug 9.

PMID:
27464945
7.

Cost analysis of multiple sclerosis in Brazil: a cross-sectional multicenter study.

da Silva NL, Takemoto ML, Damasceno A, Fragoso YD, Finkelsztejn A, Becker J, Gonçalves MV, Tilbery C, de Oliveira EM, Callegaro D, Boulos FC.

BMC Health Serv Res. 2016 Mar 24;16:102. doi: 10.1186/s12913-016-1352-3.

8.

Validation and cross-cultural adaptation of sexual dysfunction modified scale in multiple sclerosis for Brazilian population.

Silva RA, Olival GS, Stievano LP, Toller VB, Jordy SS, Eloi M, Tilbery CP.

Arq Neuropsiquiatr. 2015 Aug;73(8):681-7. doi: 10.1590/0004-282X20150078.

9.

Validation survey of the impact of urinary incontinence (IIQ-7) and inventory of distress urogenital (UDI-6) - the short scales - in patients with multiple sclerosis.

Stievano LP, Olival GS, Silva RA, Toller VB, Carabetta EG, da Cunha ET, Moreira Rde J, Eloi M, Tilbery CP.

Arq Neuropsiquiatr. 2015 Jan;73(1):46-51. doi: 10.1590/0004-282X20140218. Epub 2015 Jan 1.

10.

Central nervous system infectious diseases mimicking multiple sclerosis: recognizing distinguishable features using MRI.

Rocha AJ, Littig IA, Nunes RH, Tilbery CP.

Arq Neuropsiquiatr. 2013 Sep;71(9B):738-46. doi: 10.1590/0004-282X20130162. Review.

11.

Multiple sclerosis and herpesvirus interaction.

Olival GS, Lima BM, Sumita LM, Serafim V, Fink MC, Nali LH, Romano CM, Thomaz RB, Cavenaghi VB, Tilbery CP, Penalva-de-Oliveira AC.

Arq Neuropsiquiatr. 2013 Sep;71(9B):727-30. doi: 10.1590/0004-282X20130160. Review.

12.

Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis.

Olival GS, Cavenaghi VB, Serafim V, Thomaz RB, Tilbery CP.

Arq Neuropsiquiatr. 2013 Aug;71(8):516-20. doi: 10.1590/0004-282X20130081.

13.

The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.

Papais-Alvarenga RM, Vasconcelos CC, Alves-Leon SV, Batista E, Santos CM, Camargo SM, Godoy M, Lacativa MC, Lorenti M, Damasceno B, Damasceno A, Brum D, Barreira AA, Guimarães Rocha MS, Alvarenga H, Tilbery CP.

Mult Scler. 2014 Mar;20(3):374-81. doi: 10.1177/1352458513495580. Epub 2013 Aug 22.

PMID:
23970504
14.

Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity?

Fernandes AM, Duprat Ade C, Eckley CA, Silva Ld, Ferreira RB, Tilbery CP.

Braz J Otorhinolaryngol. 2013 Aug;79(4):460-5. doi: 10.5935/1808-8694.20130082. English, Portuguese.

15.

Genomic analysis of ERVWE2 locus in patients with multiple sclerosis: absence of genetic association but potential role of human endogenous retrovirus type W elements in molecular mimicry with myelin antigen.

do Olival GS, Faria TS, Nali LH, de Oliveira AC, Casseb J, Vidal JE, Cavenaghi VB, Tilbery CP, Moraes L, Fink MC, Sumita LM, Perron H, Romano CM.

Front Microbiol. 2013 Jun 26;4:172. doi: 10.3389/fmicb.2013.00172. eCollection 2013. Erratum in: Front Microbiol. 2013;4:345.

16.

Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, Frederiksen J, Gass A, Gama H, Tilbery CP, Rocha AJ, Flores J, Barkhof F, Seewann A, Palace J, Yousry T, Montalban X, Enzinger C, Fazekas F.

J Neurol. 2013 Aug;260(8):2016-22. doi: 10.1007/s00415-013-6918-y. Epub 2013 Apr 26.

PMID:
23620065
17.
18.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
19.

Clinical predictors of response to immunomodulators for multiple sclerosis.

Olival GS, Lima LC, Lima GP, Tilbery CP.

Arq Neuropsiquiatr. 2012 Jan;70(1):12-6.

Supplemental Content

Loading ...
Support Center